Article
Fort Lauderdale, FL-Pharmacologic enhancement for retinal repair surgery continues to be a viable strategy, and the promise of its use to improve outcomes may be fulfilled as drug therapy enters a new era, said Mark S. Blumenkranz, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.